患者自报结局指标能否作为青光眼临床试验终点:UKGTS证据
基于英国青光眼治疗研究(UKGTS)的二次分析,比较拉坦前列素与安慰剂组在健康相关和视功能相关患者自报结局指标(PROMs)上的变化。结果显示两组PROMs平均变化无显著差异,但青光眼特异性PROMs在稳定与进展患者间有显著差异。PROMs可能不够敏感,不足以作为早期青光眼临床试验的主要终点。
要点
- 拉坦前列素与安慰剂组在EQ-5D、SF-36、GQL-15和GAL-9的平均变化无显著差异。
- 青光眼特异性PROMs(GQL-15、GAL-9)在稳定与进展患者间差异显著。
- 通用健康PROMs在稳定与进展患者间无显著差异。
核心结论
- 在UKGTS中,拉坦前列素与安慰剂组在健康相关和视功能相关PROMs的平均变化相似,PROMs可能不够敏感,不足以作为早期青光眼临床试验的主要终点。
研究设计与样本
- 多中心、随机、三盲、安慰剂对照试验(UKGTS),新诊断开角型青光眼患者接受拉坦前列素或安慰剂滴眼液,观察24个月。
- 纳入有基线和退出时PROMs的患者,治疗组n=182,安慰剂组n=168。
主要发现
- 治疗组与安慰剂组PROMs平均百分比变化无统计学显著差异:EQ-5D P=0.98,EQ-5D视觉模拟量表P=0.88,SF-36 P=0.94,GQL-15 P=0.66,GAL-9 P=0.87。
- 稳定患者(n=272)与进展患者(n=78)在青光眼特异性PROMs上差异显著:GQL-15 P=0.02,GAL-9 P=0.02。
- 稳定与进展患者在通用健康PROMs上无显著差异:EQ-5D P=0.62,EQ-5D视觉模拟量表P=0.23,SF-36 P=0.65。
关键数值与推荐
- PROMs包括通用健康(EQ-5D、SF-36)和青光眼特异性(GQL-15、GAL-9)量表,在基线和退出时完成。
- 进展由视野变化(主要结局)判定,稳定患者n=272,进展患者n=78。
临床怎么用
- 在早期青光眼临床试验中,不宜将PROMs作为主要终点;青光眼特异性PROMs可考虑用于反映进展相关生活质量变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The United Kingdom Glaucoma Treatment Study (UKGTS) demonstrated the effectiveness of an intraocular pressure-lowering drug in patients with glaucoma using visual field progression as a primary outcome. The present study tested the hypothesis that responses on patient-reported outcome measures (PROMs; secondary outcome measure) differ between patients receiving a topical prostaglandin analog (latanoprost) or placebo eye drops in UKGTS. DESIGN: Multicenter, randomized, triple-masked, placebo-controlled trial. PARTICIPANTS: Newly diagnosed glaucoma patients in the UKGTS with baseline and exit PROMs (n = 182 and n = 168 patients from the treatment and placebo groups, respectively). METHODS: In the UKGTS (trial registration number, ISRCTN96423140), patients with open-angle glaucoma were allocated to receive latanoprost (treatment) or placebo; the observation period was 24 months. Patients completed general health PROMs (European Quality of Life in 5 Dimensions [EQ-5D] and 36-item Short Form [SF-36]) and PROMs specific to glaucoma (15-item Glaucoma Quality of Life [GQL-15] and 9-item Glaucoma Activity Limitation [GAL-9]) at baseline and exit from the trial. Percentage changes between measurement on PROMs were calculated for each patient and compared between treatment arms. In addition, differences between stable patients (n = 272) and those with glaucomatous progression (n = 78), as determined by visual field change (primary outcome), were assessed. MAIN OUTCOME MEASURE: PROMs on health-related and vision-related quality of life. RESULTS: Average percentage change on PROMs was similar for patients in both arms of the trial, with no statistically significant differences between treatment and placebo groups (EQ-5D, P = 0.98; EQ-5D visual analog scale, P = 0.88; SF-36, P = 0.94, GQL-15, P = 0.66; GAL-9, P = 0.87). There were statistically significant differences between stable and progressing patients on glaucoma-specific PROMs (GQL-15, P = 0.02; GAL-9, P = 0.02), but not on general health PROMs (EQ-5D, P = 0.62; EQ-5D visual analog scale, P = 0.23; SF-36, P = 0.65). CONCLUSIONS: Average change in PROMs on health-related and vision-related quality of life was similar for the treatment and placebo groups in the UKGTS. The PROMs used may not be sensitive enough to function as primary end points in clinical trials when participants have newly diagnosed early-stage glaucoma.
引用
- Jones L, Garway-Heath DF, Azuara-Blanco A, et al. Are Patient Self-Reported Outcome Measures Sensitive Enough to Be Used as End Points in Clinical Trials?: Evidence from the United Kingdom Glaucoma Treatment Study. Ophthalmology. 2018. PMID: 30273622. doi:10.1016/j.ophtha.2018.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。